US 9962390
Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
granted A61KA61K31/5375A61K47/38
Quick answer
US patent 9962390 (Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration) held by KOREA UNITED PHARM. INC. expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- KOREA UNITED PHARM. INC.
- Grant date
- Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K31/5375, A61K47/38, A61K9/0053, A61K9/2054